Publication Name	World Journal of Gastroenterology
Manuscript ID	5393
Country	China

Received	2013-09-04 17:17
Peer-Review Started	2013-09-05 09:24
To Make the First Decision	2013-09-27 16:55
Return for Revision	2013-09-29 10:29
Revised	2013-10-11 11:11
Second Decision	2013-10-17 14:35
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-10-18 07:53
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-10-31 09:17
Typeset the Manuscript	2014-01-06 10:26
Publish the Manuscript Online	2014-01-20 17:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Meta-Analysis
Article Title	S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: A meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Guo-Fang Liu, Dong Tang, Ping Li, Su Wang, Ya-Xiang Xu, Ai-Hua Long, Nian-Lan Zhou, Li-Li Zhang, Jie Chen and Xiao-Xing Xiang
Funding Agency and Grant Number
Corresponding Author	Xiao-Xing Xiang, Adjunct Professor, Chief Physician, Department of Gastroenterology and Hepatology, Subei People’s Hospital of Jiangsu Province (Clinical Medical College of Yangzhou University), Nantong West Road No.98, Yangzhou 225000, Jiangsu Province, China. yzxiangxx@sina.com
Key Words	S-1; Advanced gastric cancer; Meta-analysis; Overall survival; Chemotherapy
Core Tip	This is the first meta-analysis aimed to detect whether S-1-based combination therapy would be more effective and safer than S-1 monotherapy in patients with advanced gastric cancer (AGC). In the meta-analysis, the S-1-based combination therapy group shows great advantages of achieving better overall survival, progression-free survival and overall response rate for AGC compared with the S-1 monotherapy group. The grade 3-4 adverse events in the combination therapy group might be overcome with medical therapy. S-1-based combination therapy should be used as a standard chemotherapeutic regimen for AGC, at least in Asia.
Publish Date	2014-01-20 17:10
Citation	Liu GF, Tang D, Li P, Wang S, Xu YX, Long AH, Zhou NL, Zhang LL, Chen J, Xiang XX. S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: A meta-analysis. World J Gastroenterol 2014; 20(1): 310-318
URL	http://www.wjgnet.com/1007-9327/full/v20/i1/310.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i1.310

Full Article (PDF)	WJG-20-310.pdf
Full Article (Word)	WJG-20-310.doc
Manuscript File	5393-Review.doc
Answering Reviewers	5393-Answering reviewers.pdf
Copyright License Agreement	5393-Copyright assignment.pdf
Peer-review Report	5393-Peer review(s).pdf
Scientific Editor Work List	5393-Scientific editor work list.doc